EcoDrugPlus

Purinergic Receptor P2y12

Ensembl ID : ENSORLG00000025320
Gene Symbol: P2RY12
4 Cross references
180 Possible Orthologues:

Purinergic Receptor P2y2, Tandem Duplicate 1

Ensembl ID : ENSORLG00000010300
Gene Symbol: P2RY2.1
3 Cross references
197 Possible Orthologues:

Putative N-Acetylated-Alpha-Linked Acidic Dipeptidase

Ensembl ID : ENSORLG00000024171
Gene Symbol: LOC105355510
3 Cross references
338 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSORLG00000001785
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSORLG00000022652
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSORLG00000017231
Gene Symbol: RIPK1L
4 Cross references
197 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSORLG00000018110
Gene Symbol: RAMP1
4 Cross references
191 Possible Orthologues:

Receptor Activity-Modifying Protein 1

Ensembl ID : ENSORLG00000022584
Gene Symbol: LOC101165131
3 Cross references
184 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4

Ensembl ID : ENSORLG00000002392
Gene Symbol: SI:CH73-383L1.1
4 Cross references
230 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta

Ensembl ID : ENSORLG00000018939
Gene Symbol: LOC101169916
3 Cross references
203 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSORLG00000001734
Gene Symbol: RPTOR
4 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSORLG00000010506
Gene Symbol: REN
4 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).